Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research demonstrates that a temperature controllable medical chilling device using thermal electric cooling technology effectively maintains constant cell temperatures, potentially improving tissue viability during hair transplant procedures.

This article proposes that transnasal evaporative cooling could advance understanding of various physiological phenomena, but reports no new clinical results; potential research directions are suggested for this concept.

A cheap stainless steel container from a retail store can store liquid nitrogen effectively for 8-12 hours, saving money for medical practitioners.

A cheap stainless steel container from a retail store can store liquid nitrogen effectively for 8-12 hours, offering a cost-effective alternative to specialized medical containers.

Scalp cooling reduces chemotherapy-induced hair loss without increasing risk of skin metastases.

This study found that cooling hair grafts during transplantation did not significantly improve the survival or growth rates of hair follicles compared to room temperature storage.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This abstract does not provide any research findings or conclusions, as it appears to be journal subscription and navigation information rather than a study summary.

In this mouse study, the researchers found that cryopreserving nanofat at -20°C maintained its viability and regenerative potential, comparable to freshly generated nanofat, supporting its potential for repeated use in regenerative applications.

This review observed that recent trials in the United States reported scalp cooling devices being effective and well tolerated for many patients in preventing chemotherapy-induced alopecia, with hair retention rates varying based on specific chemotherapy drugs and regimens.

Scalp cooling can help reduce hair loss during chemotherapy.

This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.

This study observed that micrografts stored at -20°C maintained their morphological structure better than those stored at 4°C, potentially allowing for more efficient hair transplantation procedures.

This study found that scalp cooling effectively prevented visible hair loss in over half of patients undergoing highly alopecia-inducing chemotherapy, yet cognitive appraisal of the treatment had a more significant impact on quality of life than the actual degree of hair retention.

This article reviews recent research and advancements in scalp cooling for preventing chemotherapy-induced hair loss, reporting no new clinical results.

This study found that cooling combined with antioxidants can improve scalp cooling effectiveness in preventing chemotherapy-induced alopecia by maintaining hair follicle viability and function.

This article reviews the pathophysiology of chemotherapy-induced alopecia and reports that scalp cooling can reduce hair loss by 50% in patients with early breast cancer receiving chemotherapy, without compromising survival or increasing scalp metastasis risk.

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

This article discusses the potential for scalp cooling to prevent hair loss during radiotherapy, drawing from its efficacy in chemotherapy contexts, but it provides no new experimental results.

This review examines existing evidence on scalp cooling systems to prevent or reduce chemotherapy-induced hair loss in cancer patients, noting promising results and their increasing adoption in clinical practice.

In this study, researchers found that using the Orbis II scalp cooling device in a single-center setting effectively prevented severe chemotherapy-induced alopecia in 73% of patients with various cancer types, though the authors recommend further studies to explore broader applicability and influencing factors.

This study analyzed the cost-effectiveness of scalp cooling as a means of preventing chemotherapy-induced hair loss and found it to be financially reasonable compared to dermatologic management strategies, suggesting that it should be considered for routine insurance coverage due to its cost-effectiveness.

This study found that the computer-controlled RV-01 scalp cooling device helped prevent significant hair loss in metastatic breast cancer patients treated with eribulin, with none of the 16 patients requiring a wig and experiencing minimal discomfort.

This study investigated scalp cooling in breast cancer patients undergoing chemotherapy, finding that those who reached a lower mean scalp skin temperature of 18 °C during cooling were less likely to require a wig or head covering compared to those with higher temperatures.

This study suggests that follicular unit viability during hair transplantation is best preserved at lower storage temperatures, specifically around 4 °C, and provides insights into optimal cooling practices to enhance transplant success.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

This paper examines the development of scalp cooling as a non-drug method to reduce chemotherapy-induced hair loss, addressing an emotionally challenging side effect of cancer treatment. Results are not provided in the abstract.

This study found that freezing PRP at -80 °C for up to a year maintains most growth factor levels, with EGF and IGF even higher than in fresh samples.

This study found that the novel dermal cooling system was an effective and safe treatment for reducing pigmentation in benign pigmented lesions in Asian patients, with minimal side effects.